Tag Archives: Protalix BioTherapeutics

Amicus Therapeutics (NASDAQ:FOLD) Stock Tumbles after Negative Results from Fabry

Amicus Therapeutics, Inc’s (NASDAQ:FOLD) stock fell on Friday after the Cranbury, New Jersey based company booked new negative results from a clinical inquiry of an experimental treatment for Fabry disease, a rare genetic disorder.

Amicus Therapeutics reported the medicine, migalastat, …

Posted in Healthcare, Main Post | Tagged , , , , , , , , , , , | Comments Off

Amicus Therapeutics (NASDAQ:FOLD) Soars after Positive Study Data – GSK, PLX, BMRN, FOLD

Amicus Therapeutics, Inc (NASDAQ:FOLD) on Friday reported positive preliminary results from all 4 dose cohorts in the phase 2 inquiry of the pharmacological chaperone AT2220 co-administered with enzyme replacement therapy or ERT for Pompe disease.

The results of the inquiry …

Posted in Latest Headlines, Services | Tagged , , , , , , , , , , , | Comments Off

Thursday’s top and bottom stock report

Heres a look at the Top 10 most active gainers and decliners in 5 different U.S. exchanges.

NASDAQ

Itron Inc. (NASDAQ:ITRI) had over 3.3 million shares trade through its market today while rising 21.5 percent to a current price of …

Posted in Latest Headlines, Reports | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off

Big time losers and the reasons why (PLX, THQI, TSO)

In this report: Protalix BioTherapeutics (AMEX:PLX), THQ Inc. (NASDAQ:THQI) and Tesoro Corp. (NYSE:TSO).

Protalix BioTherapeutics (AMEX:PLX) sank 12 percent on Tuesday after the company announced that it received notification from the Food and Drug Administration has extended the PDUFA goal …

Posted in Latest Headlines, Reports | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off